Skip to main content
. 2024 Jun 13;12(6):1315. doi: 10.3390/biomedicines12061315

Figure 2.

Figure 2

miR-155 2−ΔΔCt fold change among the three groups. Legend: miR-miRNA; group 1—UC patients; group 2—CDI patients; group 3 (control group)—IBS-D patients.